It has been shown that HSD17B13 variants are associated with nonalcoholic fatty liver disease (NAFLD) and HSD17B13 expression is elevated in nonalcoholic steatohepatitis (NASH) patients, or with risk of cirrhosis and hepatocellular carcinoma (HCC), while a HSD17B13 variant has been demonstrated to protect from HCC development [52–54]. Here, HSD17B13 is linked to hepatocellular carcinoma.